Safety of treatment for gastroparesis

References

• Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2008;103(3):753–763.
   PubMed Web of Science ®Google Scholar
• Parkman HP, McCallum RW. Gastroparesis: pathophysiology, presentation, and treatment. New York (NY): Humana Press; 2012.
   Google Scholar
• Hasler WL. Symptomatic management for gastroparesis: antiemetics, analgesics, and symptom modulators. Gastroenterol Clin North Am. 2015;44(1):113–126.
   PubMed Web of Science ®Google Scholar
• Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127(5):1589–1591.
   PubMed Web of Science ®Google Scholar
• Hasler WL. Gastroparesis: symptoms, evaluation, and treatment. Gastroenterol Clin North Am. 2007;36(3):619–647, ix.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37;quiz 38.
   Web of Science ®Google Scholar
• Bortolotti M, Gentilini L, Morselli C, et al. Gastroparesis refractory to prokinetics: neuromuscolar unresponsiveness or faulty bioavailability of the drug? Dig Dis Sci. 2005;50(5):882–884.
   PubMed Web of Science ®Google Scholar
• Hejazi RA, McCallum RW, Sarosiek I. Prokinetics in diabetic gastroparesis. Curr Gastroenterol Rep. 2012;14(4):297–305.
   PubMedGoogle Scholar
• Reddymasu SC, McCallum RW. Pharmacotherapy of gastroparesis. Expert Opin Pharmacother. 2009;10(3):469–484.
   PubMed Web of Science ®Google Scholar
• Brogden RN, Carmine AA, Heel RC, et al. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs. 1982;24(5):360–400.
   PubMed Web of Science ®Google Scholar
• Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11–19.
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Pehlivanov N, Sugumar A, et al. Drug insight: from disturbed motility to disordered movement–a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3(3):138–148.
   PubMedGoogle Scholar
• Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med. 1983;98(1):86–95.
   PubMed Web of Science ®Google Scholar
• Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. Neurogastroenterol Motil. 2014;26(4):521–528.
   PubMed Web of Science ®Google Scholar
• Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N Z Med J. 2015;128(1416):66–74.
   PubMedGoogle Scholar
• Spirt MJ, Chan W, Thieberg M, et al. Neuroleptic malignant syndrome induced by domperidone. Dig Dis Sci. 1992;37(6):946–948.
   PubMed Web of Science ®Google Scholar
• Sowers JR, Sharp B, McCallum RW. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. J Clin Endocrinol Metab. 1982;54(4):869–871.
   PubMed Web of Science ®Google Scholar
• van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Safety. 2010;33(11):1003–1014.
   PubMed Web of Science ®Google Scholar
• Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881–888.
   PubMed Web of Science ®Google Scholar
• Ortiz A, Cooper CJ, Alvarez A, et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421–424.
   PubMed Web of Science ®Google Scholar
• Tack J, Janssens J, Vantrappen G, et al. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology. 1992;103(1):72–79.
   PubMed Web of Science ®Google Scholar
• Ramirez B, Richter JE. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993;7(1):5–20.
   PubMed Web of Science ®Google Scholar
• Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol. 2003;98(2):259–263.
   PubMed Web of Science ®Google Scholar
• Bortolotti M, Brunelli F, Sarti P, et al. Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Aliment Pharmacol Ther. 1998;12(10):1021–1025.
   PubMed Web of Science ®Google Scholar
• Bortolotti M, Mari C, Brunelli F, et al. Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Dig Dis Sci. 1999;44(12):2439–2442.
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Wang Y, Hobson A, et al. Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol. 2013;170(7):1323–1332.
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7):745–767.
   PubMed Web of Science ®Google Scholar
• Stevens JE, Jones KL, Rayner CK, et al. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives. Expert Opin Pharmacother. 2013;14(9):1171–1186.
   PubMed Web of Science ®Google Scholar
• Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther. 2010;32(9):1102–1112.
   PubMed Web of Science ®Google Scholar
• Carbone F, Rotondo A, Andrews C et al. A controlled cross-over trial shows benefit of prucalopride for symptom control and gastric emptying in gastroparesis. UEG Week. 2015. Available from: https://uegw.congress-online.com/guest/ID56e1c851150d78/AbstractView?ABSID=12703
   Google Scholar
• Sun Y, Song G, McCallum RW. Evaluation of acotiamide for the treatment of functional dyspepsia. Expert Opin Drug Metab Toxicol. 2014;10(8):1161–1168.
   PubMed Web of Science ®Google Scholar
• Zarling EJ. Prokinetic activity of nizatidine: implications for the management of patients with gastroesophageal reflux disease. Clin Ther. 1999;21(12):2038–2046; discussion 2037.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Papathanasopoulos A, Odunsi ST. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2009;6(6):343–352.
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care. 2013;36(1):41–48.
   PubMed Web of Science ®Google Scholar
• Smith HS, Smith JM, Seidner P. Opioid-induced nausea and vomiting. Ann Palliat Med. 2012;1(2):121–129.
   PubMedGoogle Scholar
• Berger NG, Ridolfi TJ, Ludwig KA. Delayed gastrointestinal recovery after abdominal operation - role of alvimopan. Clin Exp Gastroenterol. 2015;8:231–235.
   PubMed Web of Science ®Google Scholar
• Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387–2396.
   PubMed Web of Science ®Google Scholar
• FDA requires boxed warning for promethazine hydrochloride injection [Internet]. [cited 2016 Apr 15]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm182498.htm.
   Google Scholar
• Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev. 2001;7(2):199–213.
   PubMedGoogle Scholar
• Goodin S, Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist. 2002;7(5):424–436.
   PubMed Web of Science ®Google Scholar
• Smith HS, Cox LR, Smith EJ. 5-HT3 receptor antagonists for the treatment of nausea/vomiting. Ann Palliat Med. 2012;1(2):115–120.
   PubMedGoogle Scholar
• Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 1996;52(5):773–794.
   PubMed Web of Science ®Google Scholar
• Simmons K, Parkman HP. Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis. Dig Dis Sci. 2014;59(6):1231–1234.
   PubMed Web of Science ®Google Scholar
• Munoz M, Covenas R. Safety of neurokinin-1 receptor antagonists. Expert Opin Drug Saf. 2013;12(5):673–685.
   PubMed Web of Science ®Google Scholar
• Kalpaklioglu F, Baccioglu A. Efficacy and safety of H1-antihistamines: an update. Antiinflamm Antiallergy Agents Med Chem. 2012;11(3):230–237.
   PubMedGoogle Scholar
• Scopolamine patch [Internet]. [cited 2016 Apr 15]. http://www.drugs.com/cdi/scopolamine-patch.html.
   Google Scholar
• Lau SH, Vaneaton C. Scopolamine patch withdrawal syndrome. Hosp Pharm. 2014;49(3):218–220.
   PubMedGoogle Scholar
• Bashashati M, McCallum RW. Neurochemical mechanisms and pharmacologic strategies in managing nausea and vomiting related to cyclic vomiting syndrome and other gastrointestinal disorders. Eur J Pharmacol. 2014;722:79–94.
   PubMed Web of Science ®Google Scholar
• Nasser Y, Bashashati M, Andrews CN. Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not ‘higher’. Neurogastroenterol Motil. 2014;26(4):447–454.
   PubMed Web of Science ®Google Scholar
• Bai Y, Xu MJ, Yang X, et al. A systematic review on intrapyloric botulinum toxin injection for gastroparesis. Digestion. 2010;81(1):27–34.
   PubMed Web of Science ®Google Scholar
• Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA. 2013;310(24):2640–2649.
   PubMed Web of Science ®Google Scholar
• Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737–748.
   PubMed Web of Science ®Google Scholar
• Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22–27.
   PubMedGoogle Scholar
• Tack J, Ly HG, Carbone F, et al. Efficacy of mirtazapine in patients with functional dyspepsia and weight loss. Clin Gastroenterol Hepatol. 2016;14(3):385–392.e384.
   PubMed Web of Science ®Google Scholar